Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Jan 25, 2021 3:46pm
211 Views
Post# 32378207

RE:Thtx stock..

RE:Thtx stock..One of the problems with a bought deal is the managment isn't going around doing presentations to drum up serious interest that will spill over into the post-offering period.  It sounds like THTX had known about 3 funds that were interested in the company and wanted to establish positions and they likely brought those three to Mackie to get the deal off the shelf and convince them to do it as a bought deal. So the rest just had to be crammed down in to either retail clients or a few smaller institutions. The problem is you're not going around getting a lot of big money guys interested in the company.  You're just getting the bare minimum to get a deal off so the underwriters aren't stuck with anything. 

It also sounds like some long term shareholders just had enough.  We've lost significant following on this board over the years.  Good posts used to get 100-150 views. It's nowhere near that and it's been dropping.  I sense a few of SPCeos followers have bagged and other long-haulers.  They're just exhausted from the inability to get over the hump and execute something concrete.  Like Bucknelly says, it's always tomorrow.  That attitude seems to have killed off a few holders.  I would expect you'll get more of this for another 4-8 weeks.  Probably won't see the momentum bottom until the April conf.  Sucks, but that's what their lousy deal did.

Adonis wrote: crazy how this offer killed this stock, 2 weeks of nonstop bleeding .. all other stock immediately after the offer is closed the stock begins to recover.


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse